A 19-year-old Canadian man becomes the first human cured through prime gene editing after doctors corrected a rare genetic disorder.

Infants born with alternating hemiplegia of childhood (AHC) begin experiencing episodes of paralysis and seizures by the time they are a few months old, followed by developmental delays and ...

Prime Medicine, a biotech company that set out to use its more precise approach to gene editing to develop new one-time treatments for rare diseases, is expanding its scope to more prevalent ...

Scientists use a precise form of gene editing called prime editing to correct the most common genetic mutations that cause alternating hemiplegia of childhood, a rare and severe neurological disorder ...

Keith Gottesdiener, MD, former president and CEO of Prime Medicine Prime Medicine is eliminating 25% of its workforce—about 50 jobs—in a restructuring that includes the company pivoting its prime ...

Prime Medicine, Inc. develops prime editing technologies but lacks proof of concept data despite being in the market for 6 years and IPO for 3 years. The gene editing sector is highly risky, with poor ...

Researchers at the Francis Crick Institute have demonstrated that a genetic method called "pooled prime editing" can screen hundreds of variants in a gene at once and identify which variants affect ...

The CRISPR gene editing system holds tremendous promise. It has already revolutionized biomedical research by making gene editing a straightforward process. It involves using a guide RNA molecule that ...

In a new study published in Nature, researchers from the Massachusetts Institute of Technology (MIT) showcased engineered prime editors with significantly lower rates of indel formation. “This paper ...

Prime Medicine secures up to $24 million from the CF Foundation to advance Prime Editors for cystic fibrosis treatment. Prime Medicine, Inc. has announced an agreement with the Cystic Fibrosis ...

Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. Dr. David Liu, pictured with former lab members Holly Rees ...